
MHRA grants marketing authorisation for Novartis’ Pluvicto
Radioligand therapy involves patients with advanced prostate cancer in Great Britain Advanced Accelerator Applications – a Novartis company – has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing …